INCYTE CORP

Drug pipeline (31)

Asset	Stage	Revenue	Trials	Status
ATEBRIOZ	approved	—	4	approved
JAKAFI	approved	—	4	approved
JAKAFI XR	approved	—	4	approved
MONJUVI	approved	—	0	—
NIKTIMVO	approved	—	0	—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (286)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00778700	phase2	completed	2008-10-28	2009-06-26	Incyte Corporation	A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
NCT01072266	phase1	completed	2010-01-01	2012-07-01	Incyte Corporation	A Dose-escalation Study in Subjects With Advanced Malignancies
NCT01195311	phase1	completed	2010-07-01	2013-05-01	Incyte Corporation	A Dose-escalation Study in Subjects With Advanced Malignancies
NCT03920852	phase1	completed	2019-05-30	2019-12-26	Incyte Corporation	A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis
NCT06843408	phase1_2	active_not_recruiting	2025-06-25	2027-01-06	Incyte Corporation	A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

FDA applications (8)

Application

Approved

Type

Applicant

Products

NDA 217180

2026-05-01

NDA

INCYTE CORP

BLA 761411

2024-08-14

BLA

INCYTE CORPORATION

BLA 761334

2023-03-22

BLA

INCYTE CORPORATION

NDA 215309

2021-09-21

NDA

INCYTE CORP

BLA 761163

2020-07-31

BLA

INCYTE CORPORATION